Navigation Links
Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
Date:8/4/2009

tists at Palatin. PL-3994 has an extended half-life, with reduced affinity for natriuretic peptide clearance receptors and increased resistance to neutral endopeptidase, an endogenous enzyme that degrades natriuretic peptides. The result is a drug candidate with improved pharmacokinetic and pharmacodynamic properties.

About Heart Failure

Heart failure affects over 5.7 million people in the United States, with 670,000 new cases diagnosed each year. Despite the treatment of heart failure with multiple drugs, the prognosis remains poor. There were over 1.1 million hospitalizations for heart failure in 2006 in the United States, with estimated direct and indirect costs of heart failure in the United States for 2009 of $37.2 billion.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website at www.palatin.com.

Forward-looking Statements

Statements about future expectations of Palatin Technologies, Inc., including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, marketing collaborations, and all other statements in this document other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Palatin's actual res
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
2. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
3. Palatin Technologies Receives Notification Letter from NYSE Alternext US
4. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
5. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
6. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
7. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
8. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
9. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
10. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
11. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ...
(Date:12/24/2014)... December 23, 2014 “Preparative & ... HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, ... & Agriculture) - Forecasts to 2019” provides a ... opportunities, current market trends, and strategies impacting the ...
(Date:12/24/2014)... Earlier this year in a June 24 international conference ... Cell Technology Center, LLC ( ASCTC ) focused attention on ... tissue stem cells. His title “Asymmetric Self-Renewal by Distributed ... embodied the essence of his message to congress participants. ...
(Date:12/24/2014)... On Friday, December 19, 2014, President Obama ... Resolution Appropriations Act of 2015, which for the first ... through the Congressionally Directed Medical Research Programs (CDMRP) administered ... (HA), working in conjunction with its allies on Capitol ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... July 9 Abt Bio-Pharma Solutions, Inc.,(ABS), ... economic, and,strategic commercialization solutions, is pleased to ... and business strategy, has been promoted to,Executive ... succeeding Susan Windham-Bannister, who has been appointed,President ...
... Provides expertise in high-growth therapeutic areas to pharmaceutical and ... biotechnology companies ... the last year, BEVERLY HILLS, Calif., July 9 Worldwide Clinical,Trials, ... reached a milestone in establishing itself as a premier global,contract research organization ...
... July 9 Cepheid (Nasdaq:,CPHD) today announced ... on Healthcare Associated Infections, Fred Tenover, Ph.D., ... will serve as a liaison,with the Infection ... Infection (HAI) Consortium program., "The objective ...
Cached Biology Technology:Abt Bio-Pharma Solutions, Inc. Names Nandini Hadker as Executive Director, Succeeding Susan Windham-Bannister 2Abt Bio-Pharma Solutions, Inc. Names Nandini Hadker as Executive Director, Succeeding Susan Windham-Bannister 3Worldwide Clinical Trials Emerges as Leading Global Contract Research Organization 2Worldwide Clinical Trials Emerges as Leading Global Contract Research Organization 3Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program 2Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program 3
(Date:1/22/2015)... /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry news, ... website design. "When we launched FindBiometrics 12 years ... O,Neill , founder and CEO of FindBiometrics. "Now it,s maturing ... the key players on a very broad scale.  We are ...
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
(Date:1/22/2015)... , January 22, 2015 , ... year  The European Patent Office to present a video ... British nominations to be featured: Christofer Toumazou and ... former finalists and winners of the Award   Starting ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3
... and Zafer Iqbal, research professors at NJIT, were awarded ... arrays of nanoscale electrical probes. Their discovery may ... variation of electrical activity inside biological cells. ... technique that allows for an array of individual, vertically-oriented ...
... DUNES NATIONAL LAKESHORE, Ind. Native bees often small, ... stinging honeybees are quite discriminating about where they ... The study found that, overall, composition of a plant ... a bee community, which may seem counterintuitive at first, ...
... of California, Riverside have made a discovery in the ... drugs and explore novel strategies for treating seizures associated ... Americans. Neurons, the basic building blocks of the ... and chemical signaling. During epileptic seizures, which generally ...
Cached Biology News:Patent for arrays of nanoscale electrical probes awarded to NJIT today 2Picky pollinators: Native bees are selective about where they live and feed 2Picky pollinators: Native bees are selective about where they live and feed 3Picky pollinators: Native bees are selective about where they live and feed 4UC Riverside neuroscientists' discovery could bring relief to epilepsy sufferers 2
Mouse monoclonal [SH-A1] to S100 alpha ( Abpromise for all tested applications). entrezGeneID: 6271 SwissProtID: P23297...
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Zinc finger MYM-type protein 3 (Zinc finger protein 261) (DXS6673E protein). [Source:Uniprot/SWISSPROT;Acc:Q14202] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: